Remy Sukhija compensation by year
MADRIGAL PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Salary | $337,500 | $461,250 | $482,813 | $387,718 |
| Bonus | $100,000 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $4,500,000 |
| Option awards | $2,724,000 | $2,048,400 | $2,725,650 | $0 |
| Non-equity incentive | $274,680 | $248,436 | $292,005 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $2,722 | $10,381 | $10,381 | $2,474,660 |
| Total | $3,438,902 | $2,768,467 | $3,510,849 | $7,362,378 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MADRIGAL PHARMACEUTICALS, INC. DEF 14A filed April 29, 2024, accession 0001193125-24-122657, and prior-year filings. Open the filing on EDGAR.
How this page was built: the MADRIGAL PHARMACEUTICALS, INC. filed document, accession 0001193125-24-122657. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 60,000 | — | $60.26 |
Per the Outstanding Equity Awards at Fiscal Year-End table in MADRIGAL PHARMACEUTICALS, INC.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.
MADRIGAL PHARMACEUTICALS’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Bill Sibold | President and Chief Executive Officer | $32,268,400 |
| Paul Friedman | Former Chief Executive Officer | $9,563,286 |
| Remy Sukhija · this page | Former Senior Vice President, Chief Commercial Officer | $7,362,378 |
| Rebecca Taub | President, Research & Development and Chief Medical Officer | $6,928,008 |
| Brian Lynch | Former Senior Vice President and General Counsel | $5,266,584 |
| Alex Howarth | Former Senior Vice President and Chief Financial Officer | $5,262,023 |
| Carole Huntsman | Chief Commercial Officer | $3,142,354 |
The full MADRIGAL PHARMACEUTICALS compensation record
free company briefThis page is one person within MADRIGAL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the MADRIGAL PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MADRIGAL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.